|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemicmales显示文摘 | Di Somma C Colao A Di Samo A Klain M Landi ML Facciolli G etal | 1998 | J Clin Endocrinol Metab1998，83，： | 1 |
| 2 | Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia:prevalence,clinical definition,and therapeutic strategy显示文摘 | Disarno A Landi ML Cappabianca P | 2001 | J Clin Endocrinol Metab2001，86，： | 1 |
| 3 | Macroprolactinoma shinkage during cabergoline treatments is greater in naive patients than in patients pretreated with other dopamine agonists:a prospective study in 110 patients显示文摘 | Colao A DiSarno A Landi ML | 2000 | J Clin Endocrinol Metab2000，85，： | 1 |
| 4 | The effect of quinagohde and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas 显示文摘 | Di Sarno A Landi ML Marzullo P | 2000 | Clin Endocrinol2000，53，1： | 1 |
| 5 | The effect of quinagolide and cabergoline,two selective dopamine receptor type 2 agonists,in the treatment of prolactinomas 显示文摘 | Di Sarno A Landi ML Marzullo P | 2002 | Clin Endocrinol (Oxf)2002，53，： | 1 |
| 6 | Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients 显示文摘 | Di Sarno A Landi ML | 2000 | J Clin Endocrinol Metab2000，85，6： | 1 |
| 7 | Resistance to caber- goline as compared with bromocriptine in hyperprelactinemia: prevalence, clinical definition ,and therapeutic strategy显示文摘 | Di Sarno A Landi ML Cappabianca P | 2001 | J Clin Endocrinol bietab2001，86，11： | 1 |
| 8 | Macroprolactinoma Shrinkage during Cabergoline Treatment Is Greater in Naive Patients Than in Patients Pretreated with Other Dopamine Agonists:A Prospective Study in 110 Patients显示文摘 | Colao A Sarno AD Landi ML | 2000 | The Journal of Clinical Endocrinology & Metabolism2000，85，6： | 1 |
| 9 | The effect of quinagolide and cabergoline,two selective dopamine receptor type2 agonists,in the treatment of prolactinomas显示文摘 | DiSamo A Landi ML Marzullo P | 2000 | Clin Endocrinol(Oxf)2000，53，： | 1 |
| 10 | Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy 显示文摘 | Di Samo A Landi ML Cappabianca P | 2001 | J Clin Endocrinol Metab2001，86，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员